Join Zealand Pharma's Upcoming Financial Results Conference Call
Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL), known for its innovative work in peptide-based medicines, is gearing up for an important event. On November 13, the company will host a conference call to discuss its third-quarter financial results for the year. This event is set to take place at 2:00 pm CET (8:00 am ET), offering an insight into the company’s latest developments and financial standing.
What to Expect During the Call
During the conference call, key figures from the company, including President and CEO Adam Steensberg, CFO Henriette Wennicke, and CMO David Kendall, will present the financial outcomes and business updates. This session will be an opportunity for investors and other stakeholders to gain a better understanding of the company’s direction and performance. Following the presentation, a Q&A session will be available, allowing participants to ask questions directly to the executives.
How to Join the Conference Call
Those interested in participating in the call should note that registration is required to receive dial-in information and a unique personal access PIN. It is advisable to register about 10 minutes before the call to ensure you have all necessary details. The registration process can be completed through the Zealand Pharma’s website.
Live Audio Webcast
If you prefer to listen to the call remotely, Zealand Pharma will provide a live, listen-only audio webcast along with accompanying slides. This enables broader access for stakeholders who may not be able to join via phone. After the event, a recording will also be made available on the company’s Investor Relations section of their website, so you can catch up at your convenience.
About Zealand Pharma
Founded in 1998, Zealand Pharma A/S has established itself as a key player within biotechnology, primarily focused on innovative peptide-based medicines. The company has successfully brought numerous drug candidates into clinical development. Currently, Zealand has two products available on the market and three candidates in late-stage development. Collaborating with various pharmaceutical companies, Zealand continues to enhance its portfolio through development and commercial partnerships.
Recent Developments
Zealand Pharma has actively pursued advancements in therapeutic solutions, which makes their upcoming conference call particularly significant. With innovative research and cutting-edge developments, the company strives to address unmet medical needs in the healthcare sector. Stakeholders and investors alike will be eager to hear updates on their latest projects and strategic direction.
Contact Information
For further inquiries regarding the conference call or other investor-related questions, Zealand Pharma has provided contact information for their Investor Relations team. Adam Lange, the Vice President of Investor Relations, is available via email, along with Neshat Ahmadi, the Investor Relations Manager, and Rachel James-Owens, Vice President of Corporate Communications & Media Relations. Each member is ready to assist and provide information crucial to understanding Zealand Pharma’s operations and outlook.
Frequently Asked Questions
1. When will the conference call take place?
The conference call is scheduled for November 13 at 2:00 pm CET (8:00 am ET).
2. How can I attend the call?
To attend, you must register to receive dial-in information and a unique access PIN.
3. Will there be a recording available after the event?
Yes, a recording of the conference call will be made available on Zealand Pharma’s website following the event.
4. Who are the key speakers on the call?
The call will feature Adam Steensberg, Henriette Wennicke, and David Kendall, who will provide insights into the company’s financial performance.
5. What is Zealand Pharma’s primary focus?
Zealand Pharma focuses on the discovery and development of innovative peptide-based medicines, having advanced several drug candidates into clinical trials.
